Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Responds to High Demand for Cannabis-Infused Beverages
- The company aims to promote healthier administration methods, eliminating the need for sweeteners to mask taste
- Lexaria’s mission is to save lives with its technology, which allows for delivery of drug molecules through ingestible means
- The company is seeing high demand in North American markets for DehydraTECH in cannabis-infused beverages
- Lexaria recently announced its entry into a CBD-beverage formulation license agreement with a Nevada-based company
Traditionally, consumers have relied on smoking to achieve higher absorption rates and fast onset of bioactive compounds such as nicotine and cannabinoids. Ingesting drugs and molecules through edibles is simply safer than inhaling them. However, the absorption of edibles has proven slow, and the taste can be unpleasant without the aid of sweeteners.
Now, thanks to a revolutionary oral technology, it is possible to deliver bioactive substances via oral ingestion without the need for the unhealthy practices of inhalational or added sweeteners.
Biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its drug-delivery platform, DehydraTECH, promoting healthier administration methods. This revolutionary oral technology increases the product’s absorption rate, reduces the time of onset and masks the undesirable taste, thus eliminating the need for sweeteners in edibles. The overall dosing is lowered, and the effectiveness of ingestible drugs and other beneficial molecules is increased. The technology offers the consumer the benefits of ingestion without the related risks that come with smoking.
“Lexaria Bioscience has the actual opportunity of changing the world,” LXRP CEO Chris Bunka noted on CEO Clips via YouTube (http://ibn.fm/cQqEd
). “We can do it through saving lives, making health improvements for any number of people who are ingesting any number of drugs or molecules like pain relief, cannabinoids or nicotine. Everybody knows that smoking is not healthy. Our technology allows for the delivery of drug molecules like cannabinoids or nicotine through ingestible means, things that you swallow. It could be a pill, a syrup or a cup of coffee. That technology, which is called DehydraTECH, is optimized to carry that drug across the intestinal wall and get more of it into your bloodstream more quickly than it otherwise could.”
Lexaria is the only company worldwide with a patent issued for oral delivery of all cannabinoids. The company currently has 10 patents granted for its cost-effective DehydraTECH, with 53 patent applications filed and pending in more than 40 countries worldwide. Lexaria is anticipating additional patents in the coming years as its intellectual property portfolio continues to grow. By out-licensing DehydraTECH, the company anticipates a steady stream of royalties from start-ups, as well as a Fortune 100 company.
Lexaria continues to see high demand in the North American markets for use of DehydraTECH in beverages. The cannabis-infused and CBD beverage markets in the United States are exploding. According to an article from Business Insider (http://ibn.fm/1EROT
), the industry could reach $600 million in the United States by 2022, outpacing other cannabis products by more than two times.
Lexaria Hemp Corp., a subsidiary of LXRP, recently announced that it has entered into a definitive five-year agreement with a Nevada-based company to provide the patented DehydraTECH for use in certain CBD-based beverages (http://ibn.fm/FlDSU
). These beverages are expected to be produced and sold across the United States.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP